Genetic Technologies Limited (GTG.AX)
| Previous close | 0.0030 |
| Open | 0.0030 |
| Bid | 0.0030 x 10000000 |
| Ask | 0.0040 x 249000000 |
| Day's range | 0.0030 - 0.0030 |
| 52-week range | 0.0030 - 0.0100 |
| Volume | |
| Avg. volume | 3,825,724 |
| Market cap | 27.702M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0010 |
| Earnings date | 29 Aug 2022 - 02 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.25 |
- GlobeNewswire
Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer Risk Assessment Test
MELBOURNE, Australia, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the completion of an independently developed and validated customizable Budget Impact Model (BIM), which demonstrates significant health and economic benefits directly attributed to the implementation of geneType Breast Cancer Risk Assessment Test. Breast cancer ri
- GlobeNewswire
Acquisition of global direct to consumer ecommerce business
MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor
- GlobeNewswire
Genetic Technologies drives leadership in precision medicine with Multi-Risk Test
MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re
